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ased on experiments with cultured ﬁbroblasts, the
apoptosis regulators caspase-9 and Apaf-1 are hypoth-
esized to function as tumor suppressors. To investigate
their in vivo role in lymphomagenesis, an IgH enhancer-
 
driven 
 
c-myc
 
 transgene was crossed onto Apaf-1
 
 
 
/
 
 
 
 and
 
caspase-9
 
 
 
/
 
 
 
 mice. Due to perinatal lethality, 
 
E
 
 
 
-
 
myc
 
transgenic Apaf-1
 
 
 
/
 
 
 
 or caspase-9
 
 
 
/
 
 
 
 fetal liver cells were
used to reconstitute lethally irradiated recipient mice.
B
 
Surprisingly, no differences were seen in rate, incidence, or
severity of lymphoma with loss of Apaf-1 or caspase-9, and
Apaf-1 was not a critical determinant of anticancer drug
sensitivity of 
 
c
 
-
 
myc
 
–induced lymphomas. Moreover, loss of
Apaf-1 did not promote oncogene-induced transformation
of mouse embryo ﬁbroblasts. Thus, Apaf-1 and caspase-9
do not suppress 
 
c
 
-
 
myc
 
–induced lymphomagenesis and
embryo ﬁbroblast transformation.
 
Introduction
 
Programmed cell death, or apoptosis, is a process which
removes redundant, damaged, or infected cells and has a vital
role in development, tissue homeostasis, and defense against
pathogens (Strasser et al., 2000). Genetic and biochemical
studies have uncovered a functional network of cell death
regulators (Hengartner, 2000). These regulators include
aspartate-specific cysteine proteases (caspases), which dismantle
cells by cleaving vital structural proteins, by unleashing latent
enzymes that degrade DNA, and by activating engulfment
by phagocytes. Studies with knockout and transgenic mice
have shown that mammals have two distinct apoptosis
 
signaling pathways (Strasser et al., 2000). One pathway is
activated by “death receptors” (a subgroup of the TNF-R
family) and requires caspase-8 and its activator FADD. The
other is initiated by certain developmental cues and cyto-
toxic stress, and it is regulated by pro- and antiapoptotic
members of the Bcl-2 family. Biochemical studies have shown
that in the Bcl-2–regulated pathway release of cytochrome 
 
c
 
from mitochondria promotes activation of caspase-9 by its
adaptor Apaf-1 (Wang, 2001). Experiments with knockout
mice showed that caspase-9 and its activator, Apaf-1, are
essential for normal brain development and suggested that
these molecules were also required for DNA damage or cyto-
toxic drug-induced apoptosis of fibroblasts and thymocytes
(Cecconi et al., 1998; Hakem et al., 1998; Kuida et al.,
1998; Yoshida et al., 1998).
Defects in the control of cell death cause an overgrowth of
cells that may lead to tumor formation or autoimmune disease
(Strasser et al., 2000). For example, overexpression of the
antiapoptotic protein Bcl-2 promotes the development of
lymphoma in humans and mice, particularly in combination
with oncogenic mutations that deregulate cell cycle control,
such as enforced 
 
c
 
-
 
myc
 
 expression (Mufti et al., 1983; Vaux
et al., 1988; Strasser et al., 1990). Based on a report that
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mouse embryo fibroblasts (MEFs) lacking Apaf-1 or cas-
pase-9 displayed reduced 
 
c
 
-
 
myc
 
–induced cell death and en-
hanced 
 
myc
 
 plus mutant 
 
ras
 
-mediated transformation, it has
been hypothesized that Apaf-1 and caspase-9 function as tu-
mor suppressors (Soengas et al., 1999). However, this exper-
imental system does not study the progress of tumorigenesis
as it occurs in vivo. To investigate the role of Apaf-1 and cas-
pase-9 in tumorigenesis in vivo, an immunoglobulin heavy
chain gene enhancer-driven (
 
E
 
 
 
) 
 
c
 
-
 
myc
 
 transgene, which
provokes the development of B cell lymphomas (Adams et
al., 1985; Harris et al., 1988), was introduced onto the
Apaf-1
 
 
 
/
 
 
 
 and caspase-9
 
 
 
/
 
 
 
 backgrounds. Our work showed
that Apaf-1 and caspase-9 do not function as tumor suppres-
sors in 
 
myc
 
-induced lymphomagenesis and that Apaf-1 is not
a critical determinant of the responsiveness of 
 
myc
 
-induced
lymphomas to chemotherapeutic drugs and 
 
 
 
-irradiation.
Furthermore, we were unable to reproduce the findings that
loss of Apaf-1 enhances oncogene-induced transformation of
MEFs. These results demonstrate that cell death inducers
other than Apaf-1 and caspase-9 play critical roles as tumor
suppressors in cells overexpressing 
 
c
 
-
 
myc
 
.
 
Results
 
Loss of Apaf-1 or caspase-9 does not accelerate
 
E
 
 
 
-
 
myc
 
 transgene-induced lymphomagenesis
 
An 
 
E
 
 
 
-
 
myc
 
 transgene was introduced onto the Apaf-1
 
 
 
/
 
 
 
and caspase-9
 
 
 
/
 
 
 
 backgrounds. Because most Apaf-1
 
 
 
/
 
 
 
 or
caspase-9
 
 
 
/
 
 
 
 mice die around embryonic day 16.5 (E16.5)
due to brain malformation (Cecconi et al., 1998; Hakem et
al., 1998; Kuida et al., 1998; Yoshida et al., 1998), fetal liver
cells from 
 
E
 
 
 
-
 
myc
 
 transgenic Apaf-1
 
 
 
/
 
 
 
 or caspase-9
 
 
 
/
 
 
 
E14.5 embryos (
 
n
 
 
 
  
 
10 C57BL/6(Ly5.2) background) were
used to reconstitute lethally irradiated C57BL/6(Ly5.1)
mice. As controls, we reconstituted recipients with fetal liver
cells from E14.5 wild-type, 
 
E
 
 
 
-
 
myc
 
 transgenic, or 
 
E
 
 
 
-
 
myc
 
/
 
E
 
 
 
-
 
bcl
 
-2 double transgenic embryos. Recipient mice were
examined for preneoplastic abnormalities and for rate and
incidence of lymphoma. Mice were killed when noted to be
sick, and lymphomas were studied histologically and by
staining with cell surface marker–specific mAbs. Polymor-
phisms at the Ly5 locus allowed verification that recipients
were efficiently reconstituted with donor-derived hemopoi-
etic cells and that lymphomas were derived from donor cells.
Six cohorts of mice were reconstituted and followed: 
 
E
 
 
 
-
 
myc
 
/Apaf-1
 
 
 
/
 
 
 
, 
 
n
 
 
 
  
 
60 mice for 44 wk (mean); 
 
E
 
 
 
-
 
myc
 
/
Apaf-1
 
 
 
/
 
 
 
, 
 
n
 
 
 
  
 
51 for 61 wk; 
 
E
 
 
 
-
 
myc
 
/Apaf-1
 
 
 
/
 
 
 
, 
 
n
 
 
 
  
 
39
for 52 wk; 
 
E
 
 
 
-
 
myc
 
/caspase-9
 
 
 
/
 
 
 
, 
 
n
 
 
 
  
 
34 for 44 wk; 
 
E
 
 
 
-
 
myc
 
/caspase-9
 
 
 
/
 
 
 
, 
 
n 
 
  
 
10 for 62 wk; and 
 
E
 
 
 
-
 
myc
 
/
 
E
 
 
 
-
 
bcl
 
-2,
 
n
 
 
 
  22 for 19 wk. Immunofluorescent staining with anti-
bodies to Ly5.1 and Ly5.2 and FACS
® analysis demon-
strated that for 61 out of 66 recipient mice tested, reconsti-
tution of the hemopoietic system was  80%. Surface
immunostaining of tumor cells from E -myc/Apaf-1
 / ,
E -myc/Apaf-1
 / , and E -myc/caspase-9
 /  stem cell re-
constituted mice confirmed that the majority were do-
nor-derived pre–B cell (Ly5.2
 B220
 sIgM
 ) or B cell
(Ly5.2
 B220
 sIgM
 ) lymphomas (Table SI, available at
http://www.jcb.org/cgi/content/full/jcb.200310041/DC1).
Lymphomas were transplantable into nonirradiated C57BL/
6 recipient mice as follows: E -myc /Apaf-1
 / , n   7/7;
E -myc /Apaf-1
 / , n   4/4; E -myc /Apaf-1
 / , n   8/8;
and E -myc / E -bcl-2, n   3/3. Apaf-1 genotype was con-
firmed by PCR, and lack of Apaf-1 protein expression was
confirmed by Western blotting (Fig. 1, A and B).
No differences were seen with the loss of Apaf-1 in the
severity of E -myc lymphoma, as determined by peripheral
blood lymphocytosis or spleen size. An increase in leuke-
mic transformation was seen more frequently in mice with
Bcl-2 overexpression although the splenomegaly was simi-
lar in all genotypes (Fig. 2). The severity of multi-organ in-
volvement by lymphoma was determined by histologic
analysis of bone marrow, spleen, lymph nodes, liver, lung,
kidney, and heart (scored blinded as to genotype of sec-
tion), and no increase in severity was observed for either
the heterozygote or homozygote deficiency for either Apaf-1
or caspase-9 (unpublished data).
Figure 1. Genotyping of lymphomas and lymphoma-derived cell 
lines. (A) Apaf-1 allele-specific PCR and (B) Western blot analysis of 
lymphomas and lymphoma cell lines. A small amount of Apaf-1 
protein was detected in some E -myc/Apaf-1
 /  lymphoma samples, 
most likely due to contaminating recipient-derived stromal tissue, as 
no Apaf-1 protein was detected in the cell lines derived from these 
lymphomas.
Figure 2. Hematologic parameters of mice with lymphoma. 
(A) Total peripheral blood white cell count from mice with lymphoma 
at time of sacrifice. (B) Spleen weight from mice with lymphoma. Data 
represent arithmetic means   SD of 3–12 mice of each genotype.Apaf-1 does not suppress myc-induced lymphomagenesis | Scott et al. 91
Sick animals were killed and autopsied and, with the ex-
ception of a small number of poorly reconstituted mice
morbid with anemia or infection, were found to suffer
from E -myc lymphoma. The rate of lymphoma onset in
mice reconstituted with an E -myc /Apaf-1
 /  hemopoi-
etic system was delayed (50% survival: 57 wk; Fig. 3 A)
compared with that observed for unmanipulated C57BL/6
E -myc transgenic mice (50% survival: 14 wk; unpub-
lished data). Despite the increase in tumor latency seen in
the reconstituted system, which was also reported by
Schmitt et al. (2002), and for which the reason is presently
unknown, marked acceleration of lymphomagenesis was
seen for mice reconstituted with a E -myc/E -bcl-2 he-
mopoietic system (50% survival: 10 wk, Kaplan-Meier
analysis log-rank P   0.001 for E -myc/E -bcl-2 vs. E -
myc; Fig. 3 A). In contrast, loss of one or both alleles of
Apaf-1 did not increase the rate or incidence of lymphoma
(50% survival: E -myc/Apaf-1
 /  57 wk; E -myc/Apaf-
1
 /  53 wk; and E  myc/Apaf-1
 /  59 wk; Kaplan-Meier
analysis log-rank P   0.9 for E -myc/Apaf-1
 /  vs. E -
myc/Apaf-1
 / ; Fig. 3 A). Similarly, loss of one or both al-
leles of caspase-9 did not enhance lymphomagenesis (50%
tumor-free survival: E -myc/caspase-9
 /  57 wk; E -myc/
caspase-9
 /  52 wk; and E -myc/caspase-9
 /  54 wk; Kap-
lan-Meier analysis log-rank P   0.9 for E -myc/caspase-
9
 /  vs. E -myc/caspase-9
 / ; Fig. 3 B). When all causes
of mortality were included in the analysis (overall survival),
we also found no increase in, or acceleration of, death with
loss of Apaf-1 or caspase-9 (Fig. S1, available at http://
www.jcb.org/cgi/content/full/jcb.200310041/DC1).
No loss of heterozygosity, determined by PCR as loss of
the wild-type allele (Fig. 1), was observed for Apaf-1 in ei-
ther lymphomas (0/19) or cell lines derived from these tu-
mors (0/6), indicating that loss of Apaf-1 is not selected for,
nor is haplo-insufficiency limiting in, c-myc–induced lym-
phoma development in vivo (Fig. 3) or for growth of lym-
phoma cell lines in culture (Fig. 4).
Loss of Apaf-1 does not render E -myc lymphomas 
resistant to anticancer therapy
It has been hypothesized that Apaf-1 and caspase-9 are not
only required for tumor suppression but are also essential for
 -radiation– or chemotherapeutic drug–induced apoptosis
of tumor cells (Soengas et al., 1999; Jia et al., 2001). There-
fore, we generated several independent cell lines from E -
myc lymphomas that were either Apaf-1
 /  or Apaf-1
 / 
and exposed them to a range of cytotoxic stimuli. Variability
in response to apoptotic stimuli was seen for all genotypes,
suggesting that the immortalizing process in vitro selects for
a range of death-response phenotypes; the range of variation
was similar between lymphomas that were Apaf-1
 / , Apaf-
1
 / , or Apaf-1
 / . Compared with E -myc/Apaf-1
 /  lym-
phoma-derived cell lines, a small reduction in sensitivity to
etoposide and  -radiation was observed for E -myc/Apaf-
1
 /  lymphoma lines at 24 h, however, by 72 h no differ-
ence in cell survival was apparent with loss of Apaf-1 (Fig.
4). As previously shown for nontransformed Apaf-1
 /  and
caspase-9
 /  lymphocytes (Marsden et al., 2002), the dying
E -myc/Apaf-1
 /  lymphoma cells exhibited classical fea-
tures of apoptosis, such as early surface exposure of phos-
phatidylserine (detected by staining with Annexin V; un-
published data). These results indicate that Apaf-1 is not
Figure 3. E -myc lymphoma onset is not affected by loss of Apaf-1 
or caspase-9. Fetal liver cells from E -myc transgenic Apaf-1
    or 
Apaf-1
 /  or E -myc transgenic caspase-9
 /  or caspase-9
 /  E14.5 
embryos were used to reconstitute lethally irradiated mice. As con-
trols, recipients were reconstituted with fetal liver cells from E14.5 
wild-type, E -myc transgenic, or E -myc/E -bcl-2 double transgenic 
embryos. Mice were killed when noted to be sick and were found 
to suffer from E -myc lymphoma, with the exception of a small 
number of poorly reconstituted mice morbid with anemia or infection. 
(A and B) Kaplan-Meier analysis of tumor-free survival (weeks).
Figure 4. Sensitivity of lymphoma-derived cell lines to apoptotic 
stimuli. Stable cell lines were derived from fresh lymphomas and 
sorted by flow cytometry using a modified FACSII
® or FACStar. For 
cell death analysis, viable cells (negative for PI) were cultured in DME 
at a concentration of 0.2–0.5   10
6 cells/ml in 96-well flat bottom 
microtiter plates. Medium alone (A), 100 nM dexamethasone (B), 
10  g/ml etoposide (C,) and 10 Gy  -irradiation (D). E -myc (open 
square), E -myc/Apaf-1
 /  (triangle, hashed line), E -myc/Apaf-1
 /  
(closed circle). Two to three independently derived lines per genotype.92 The Journal of Cell Biology | Volume 164, Number 1, 2004
limiting for cancer therapy–induced apoptosis and killing of
E -myc lymphomas.
Loss of Apaf-1 does not cause an increase in E -myc 
transgene-induced B lymphoid cellularity
We also examined whether loss of Apaf-1 had an effect on
the preneoplastic B cell phenotype induced by E -myc
transgene expression. This was done by measuring total leu-
kocyte numbers and numbers of B lymphocytes in blood,
bone marrow, spleen, and lymph nodes in mice reconsti-
tuted with E -myc/Apaf-1
 /  or E -myc/Apaf-1
 /  fetal
liver cells 12 wk after transplantation (range   5–27, and
median and mean   12 wk), an earlier time than most re-
constituted mice succumbed to lymphoma (range   5–77,
median   27, and mean   31 wk). Absence of significant
numbers of tumor cells in all mice used for these analyses
was proven by showing that transplanting 10
6 spleen cells
into nonirradiated histocompatible mice did not cause lym-
phoma (unpublished data). No differences in pre–B cell
(B220
 sIgM
 ) or B cell (B220
 sIgM
 ) numbers were
found between mice reconstituted with E -myc/Apaf-1
 / 
or E -myc/Apaf-1
 /  stem cells (Fig. 5). As previously re-
ported (Langdon et al., 1986), E -myc expression caused a
reduction in numbers of mature B cells in bone marrow
compared with wild-type mice; this is thought to be a conse-
quence of the proapoptotic and differentiation inhibiting ef-
fects of myc in B lymphocytes.
Loss of Apaf-1 does not inhibit myc-enhanced 
apoptosis in B lymphoid cells
Deregulated  c-myc expression increases susceptibility of
lymphocytes and many other cell types to a broad range
of apoptotic stimuli (Pelengaris et al., 2002). Therefore,
we FACS
®-sorted preneoplastic E -myc/Apaf-1
 /  and E -
myc/Apaf-1
 /  pre–B cells and B cells from reconstituted
animals and investigated whether loss of Apaf-1 rendered
them resistant to cytokine withdrawal, dexamethasone, eto-
poside, or  -radiation in culture. A modest ( 1.5-fold) re-
duction in sensitivity to these stress stimuli was observed for
pre–B cells at 6, 24, and 48 h (P   0.05 at 24 h, t test);
however, by 72 h, no consistent difference in cell death was
apparent with loss of Apaf-1 (Fig. 6, A–D). These conclu-
sions were based on short-term survival assays. A more
stringent measurement of cell survival is to determine
whether cells retain colony forming potential. As pro/pre–B
Figure 5. Hematologic parameters of preneoplastic mice. (A) Bone 
marrow cellularity (per 2 femurs) and B cell and pre–B cell counts. 
(B) Spleen cellularity. Data represent the arithmetic means   SD from 
four to eight mice of each genotype.
Figure 6. Sensitivity of preneoplastic B lymphoid cells to apoptotic 
stimuli. Pre–B cells (B220
 sIg
 ) and B cells (B220
 sIg
 ) were purified 
from bone marrow and lymph nodes, respectively, of recipient mice 
showing no signs of lymphoma by immunofluorescent staining and 
sorting on a FACStar, DIVA, or MoFlo. (A–D) Sensitivity of preneo-
plastic B cells to the following apoptotic stimuli: culture in the 
absence of cytokines (A), 100 nM dexamethasone (B), 10  g/ml eto-
poside (VP16; C), and 10 Gy  -irradiation (D). E -myc (open circle), 
E -myc/Apaf-1
 /  (closed circle), Apaf-1
 /  (open square), and 
Apaf-1
 /  (closed square). Cells were cultured and viability was 
determined over 6–72 h as described in Fig. 4 legend. (E) The colony-
forming potential of pro/pre–B cells from the bone marrow of C57BL/
6-Ly5.1 mice reconstituted with E -myc or E -myc/Apaf-1
 /  fetal 
liver stem cells in limiting dilution after no treatment or after exposure 
to 2.5 Gy  -radiation or 1.0, 0.3, 0.03  g/ml etoposide (VP16). B cell 
colonies consisting of at least 20 cells were scored blinded as to 
genotype using an inverted microscope at day 10, and the cloning 
frequency was determined using limiting dilution analysis. Clonoge-
nicity is less than or equal to the value shown. Data represent 
arithmetic means   SD of 3–10 mice of each genotype.Apaf-1 does not suppress myc-induced lymphomagenesis | Scott et al. 93
cells can be grown as colonies on stromal cells in the pres-
ence of IL-7 (Rolink et al., 1991), we investigated whether
loss of Apaf-1 had an effect on clonogenic survival of E -
myc pro/pre–B cells. E -myc/Apaf-1
 /  pro/pre–B cells
formed colonies at a frequency of 1/14   12 (Fig. 6 E) and
loss of Apaf-1 did not alter this (E -myc/Apaf-1
 /  1/12  
8; P   0.5). When colony forming cells were exposed to
 -radiation (2.5 Gy) or a 6-h treatment with etoposide
(0.3–1.0  g/ml), the clonal frequency decreased by 10–80-
fold, and loss of Apaf-1 did not afford any protection (P  
0.6; Fig. 6 E). Thus, the protection against apoptosis seen
at early time points (24–48 h) in short-term survival assays
could be compensated for in the longer term by other apop-
totic regulators. Collectively, these results demonstrate that
Apaf-1 plays no, or only a minor, role in cell death that is
enhanced by deregulated c-myc expression.
Loss of Apaf-1 does not enhance oncogene-induced 
transformation of MEFs
As aforementioned, the hypothesis that Apaf-1 and cas-
pase-9 function as tumor suppressor genes was based on the
observation that the loss of these proteins increased colony
formation of MEFs infected with viruses encoding the on-
cogenes  myc plus or minus mutant ras (Soengas et al.,
1999). We performed similar experiments with the adeno-
viral oncogene E1A or c-myc, plus or minus mutant ras, but
found no increase in oncogene-induced colony formation
of early passage MEFs with loss of Apaf-1 (Fig. 7). In short-
term assays, MEFs lacking Apaf-1, Bax, or p53 or express-
ing Bcl-xL were resistant to apoptosis induction in response
to serum withdrawal or UV-C (Fig. 7 A), and similar re-
sults were obtained with etoposide, actinomycin D, stauro-
sporine, doxorubicine, cisplatin, and taxol (not depicted).
However, in longer-term studies requiring cellular transfor-
mation, loss of Apaf-1 did not result in a growth advantage
(Fig. 7 B). In contrast, a large increase in colony formation
was observed when MEFs from p53 or Bax-deficient mice
were infected with E1A plus mutant ras- or c-myc plus mu-
tant ras-containing viruses, but not when Apaf-1
 /  MEFs
were used (Fig. 7 B). All MEFs grew at comparable rates
under standard cell culture conditions (Fig. S2 A, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200310041/
DC1), and the oncogenic proteins were expressed at similar
levels in each of the MEFs infected with oncogene-contain-
ing retroviruses (Fig. S2 B). Comparable results were ob-
tained in three independent experiments performed with
separately derived sets of MEFs of each genotype. In addi-
tion, the inability of the Apaf-1 deficiency to enhance
transformation in focus assays was observed in MEFs from
two independently generated knockout mouse lines (Cec-
coni et al., 1998; Yoshida et al., 1998; unpublished data).
The ability of p53 and Bax to suppress cell transformation
in this system is consistent with observations that induc-
tion of apoptosis is critical for p53’s tumor suppressive ef-
fects (Schmitt et al., 2002) and that such apoptosis can be
activated via Bax (McCurrach et al., 1997; Zhang et al.,
2000). Therefore, under the conditions we used, a block to
apoptosis upstream of the mitochondria can promote
transformation, which is not seen when the defect is at the
level of Apaf-1.
Discussion
Based on experiments with MEFs engineered to express the
oncogene c-myc with or without oncogenic ras, it was pro-
posed that Apaf-1 and caspase-9 function as critical tumor
suppressors (Soengas et al., 1999). We performed the first ex-
amination of the role of Apaf-1 and caspase-9 in tumorigene-
sis in whole animal experiments and found that these proteins
are not critical for suppressing myc-induced lymphomagene-
sis. Moreover, we found that Apaf-1 is not essential for myc-
enhanced apoptosis and responsiveness of myc-induced lym-
phomas to anticancer therapy. Finally, we have been unable
to reproduce the results that indicated a role for Apaf-1 in
suppressing oncogene-induced transformation in MEFs.
One possible explanation for the differences between our
results and those published previously (Soengas et al., 1999)
could be that we used freshly isolated Apaf-1
 /  MEFs (pas-
sage 2 or 3) and a rapid selection procedure for infected cells
using cotransduction techniques rather than sequential se-
lection, which minimizes the risk of up-regulating growth-
promoting genes. In contrast, the more protracted transduc-
tion and sequential selection procedure used in the previous
study (Soengas et al., 1999) may have resulted in significant
opportunities for up-regulation of or, less likely, mutation of
growth-promoting genes in the MEFs tested. The accumula-
tion of growth-promoting changes may in some way be en-
Figure 7. Loss of Apaf-1 protects MEFs against rapid p53-dependent 
apoptosis, but not against p53-dependent suppression of long-term 
proliferative survival. (A) Early passage MEFs of the indicated geno-
types were retrovirally transduced to express E1A plus mutant ras or 
E1A, mutant ras, and Bcl-xL. Apoptotic cell death was assessed by 
staining with FITC-coupled Annexin V plus PI and flow cytometry at 
the indicated time points after serum withdrawal or 24 h after UV 
radiation, and the mean fractions of Annexin V
 /PI
  viable cells are 
given. (B) Early passage MEFs of the indicated genotypes were retro-
virally transduced to express the indicated combinations of oncogenes. 
2 d after transduction, the cells were seeded in triplicate at low 
density in selection medium. After 7 d culture in selection medium, 
cells were fixed, stained, and, the resulting colonies, enumerated. 
Mean value   SD of three independent experiments.94 The Journal of Cell Biology | Volume 164, Number 1, 2004
hanced on an Apaf-1
 / background, implying an indirect
growth-promoting effect of loss of function of this gene,
which may have altered the composition of the MEFs used
in the Soengas et al. (1999) work.
It is possible that constant loss of a molecule (e.g., by germ-
line deletion) may allow developmental compensation to oc-
cur. In this case, different phenotypes may result from con-
stitutive loss compared with acute loss of the same molecule,
although this should not account for differences between
this paper and the Soengas et al. (1999) paper because the
MEFs used in both sets of experiments originated from mice
with germline deletion of Apaf-1. Although compensation
by proteins with similar function is a theoretical caveat on
this paper, we have not yet found evidence for up-regulation
of potentially compensatory molecules for Apaf-1 and cas-
pase-9. This is in spite of an extensive analysis being per-
formed in lymphoid cells from wild-type, Apaf-1
 / , and
caspase-9
 /  mice, the cell type relevant for this model of tu-
morigenesis, comparing expression levels and activation of
caspase-2, -3, -6, -7, -8, or -9 after exposure to a range of
death stimuli (Fig. S3, available at http://www.jcb.org/cgi/
content/full/jcb.200310041/DC1; and see Fig. 4 a in Mars-
den et al., 2002). In contrast, compensatory caspase activa-
tion has been reported in an analysis of caspase-9
 /  hepato-
cytes (Zheng et al., 2000); cell type–specific differences in
the regulation of caspase expression and/or activation may
account for the differences observed in the two works.
The E –myc lymphoma model has been used to demon-
strate the tumor suppressor activity of p53 (Hsu et al., 1995),
Arf (Eischen et al., 1999; Schmitt et al., 1999), and proapop-
totic BH3-only Bcl-2 family member Bim (O’Connor et al.,
1998; unpublished data), including the effect of haplo-insuf-
ficiency of these molecules. Thus, for at least two bona fide
tumor suppressor genes involved in abrogation of apoptosis
in  E -myc lymphoma via the Bcl-2–regulated apoptotic
pathway, the use of this model has been firmly established.
There have been no previous studies describing the effects
of loss of Apaf-1 or caspase-9 on E -myc–induced lym-
phomagenesis or lymphomagenesis in general. Retroviral
transduction of a caspase-9 dominant-negative (C9DN)
construct into E -myc/p53
 /  stem cells was used to investi-
gate the role of caspase-9 in lymphomagenesis (Schmitt et
al., 2002). Using as the endpoints of analysis selection for
cells expressing the C9DN or retention of the wild-type p53
allele, an effect of C9DN was observed; however, this was
not sufficient to accelerate lymphomagenesis, the more
stringent and meaningful parameter for analysis. Indeed,
this dominant-negative allele of caspase-9 is suspected to
have targets in addition to caspase-9 because it was shown to
block apoptotic pathways, such as Fas signaling (Srinivasula
et al., 1998), that are intact in caspase-9–deficient cells
(Hakem et al., 1998; Kuida et al., 1998). Therefore, it is
possible that the effects of C9DN on E -myc–induced lym-
phomagenesis on a p53
 /  background may have resulted
from factors other than blocking caspase-9 function.
The other evidence for a tumor suppressor role reported to
date for Apaf-1 was in human melanoma (Soengas et al.,
2001). A collection of early and metastatic melanomas and
melanoma cell lines in which a low rate of p53 mutation was
observed was analyzed, and, in a significant proportion, Apaf-1
was found to be silenced by gene methylation. Apaf-1 defi-
ciency correlated with poor response to chemotherapy and its
reexpression increased sensitivity to cytotoxic drugs. However,
these data are correlative and no studies have been reported
that demonstrated that Apaf-1 loss could accelerate tumori-
genesis in a mouse model of melanoma development. More-
over, in neuroblastoma, a tumor examined specifically because
of its similarity with melanoma, as both arise from neural crest
progenitor cells and some show N-myc gene amplification,
Apaf-1 and caspase 9 were found to be present and active in
all specimens examined (Teitz et al., 2002). Thus, although it
is possible that Apaf-1 has a cell type–restricted role in tumor
suppression, to date, there is no proof for this.
In conclusion, our studies investigated the possible roles
of Apaf-1 and caspase-9 as tumor suppressors in an in vivo
model relevant for tumorigenesis. We found no evidence to
support a proposed role for either Apaf-1 or caspase-9 as
critical tumor suppressors in c-myc–induced lymphomagene-
sis in the mouse, nor did we find evidence that Apaf-1 is a
critical determinant of anticancer drug sensitivity of c-myc–
induced lymphomas. The reason why Bcl-2 synergizes po-
tently with c-myc in tumorigenesis (Strasser et al., 1990) and
blocks  myc-enhanced apoptosis (Bissonnette et al., 1992;
Fanidi et al., 1992; Strasser et al., 1996) but loss of Apaf-1
or caspase-9 do not, is most likely due to the fact that Bcl-2
inhibits not only Apaf-1–mediated caspase-9 activation but
also other apoptotic processes. Our previous work has indi-
cated that the Bcl-2 protein family regulates activation of
caspases that initiate apoptosis by acting upstream of mito-
chondrial membrane disruption (Marsden et al., 2002).
However, there is also evidence for caspase-independent
processes regulated by Bcl-2 that might play a role in apop-
tosis induced by deregulated protooncogene expression (Mc-
Carthy et al., 1997), including preservation of mitochon-
drial membrane integrity and membrane potential (Green
and Reed, 1998). Indeed, Bcl-2 has been shown to block
apoptosis in cells lacking Apaf-1 (Haraguchi et al., 2000).
Thus, the apoptotic regulators, Apaf-1 and caspase-9, do
not have an essential suppressive role in myc-induced lym-
phomagenesis, nor does Apaf-1 have an essential role in MEFs
transformation as previously ascribed. Other regulators of
myc-induced apoptosis acting as tumor suppressors need to be
identified and mechanisms of cell specificity determined.
Materials and methods
Mice
An  E -myc transgene was introduced onto the Apaf-1
 /  (Cecconi et al.,
1998; provided by P. Gruss and F. Cecconi, Max Planck Institute, Goettingen,
Germany) and caspase-9
 /  background (Kuida et al., 1998; provided by K.
Kuida, Vertex, Inc., Cambridge, MA). Fetal liver cells from E -myc transgenic
Apaf-1
 /  or Apaf-1
 /  or E -myc transgenic caspase-9
 /  or caspase-9
 / 
E14.5 embryos were used to reconstitute lethally irradiated C57BL/6(Ly5.1)
mice. As controls, recipients were reconstituted with fetal liver cells from
E14.5 wild-type, E -myc transgenic, or E -myc/E -bcl-2 double transgenic
(Strasser et al., 1990) embryos (provided by J. Adams, S. Cory, and A. Harris,
The Walter and Eliza Hall Institute of Medical Research, Melbourne, Austra-
lia). All mouse strains used as donors were on an inbred C57BL/6(Ly5.2) ge-
netic background or had been backcrossed for  10 generations. As a further
control, we also reconstituted mice with wild-type, Apaf-1
 / , and caspase-9
 / 
E14.5 fetal liver cells, and the majority of these recipients remained healthy for
at least 70 wk, with the exception of two animals that developed radiation-
induced T cell lymphomas (in comparison, two animals expressing a myc
transgene also developed radiation-induced T cell lymphomas).Apaf-1 does not suppress myc-induced lymphomagenesis | Scott et al. 95
3-wk-old mice and E14.5 embryos were genotyped by PCR analysis of
DNA extracted from tails or heads as previously described (Marsden et al.,
2002). For timed pregnancies, the morning when vaginal plugs were de-
tected was taken as day 0. Day 14.5 pregnant mice were killed by cervical
dislocation, embryos were removed, and fetal livers were dissected under
a microscope. Fetal liver cell suspensions were prepared in balanced salt
solution containing 10% BSS-FCS. For injection, 2   10
6 cells in BSS were
injected into lethally irradiated (2   5.5Gy, 3-h interval) C57BL/6-Ly5.1
mice. To prevent infections, the transplanted animals were initially pro-
vided with water containing neomycin (Sigma-Aldrich).
Lymphoma analysis
Rate and incidence of lymphoma in cohorts of recipient mice were com-
pared by log-rank test and Kaplan-Meier analysis using the StatView
® soft-
wear. Cause of death was attributed to E -myc lymphoma if a combina-
tion of the following suggestive features were noted: presence of enlarged
spleen and/or lymph nodes, histologic evidence of invasive lymphoma,
lymphocyte count  20   10
6/ml, FACS
® profile consistent with Ly5.2
 
donor-derived lymphoma, and growth of lymphoma cells in nonirradiated
transplant recipients. For a small number of mice the cause of death was
inadequate hemopoietic reconstitution (early death defined as  28 d after
reconstitution or late death if later than 28 d after reconstitution with
spleen  50 mg and/or evidence of severe anemia), recipient-derived T cell
lymphoma (presumed secondary to irradiation), or infection.
Mice were killed when noted to be sick, peripheral blood was harvested
from the orbital plexus, lymph node and spleen suspensions were pre-
pared, and other organs were harvested. Lymphomas were studied by
staining with cell surface marker-specific mAbs followed by flow cytome-
try. Antibodies used were A201.7 anti-Ly5.1, 5.450.15.2 anti-Ly5.2, RA3–
6B2 anti-CD45R(B220), 11/26C anti-IgD, 5.1 anti-IgM (  heavy chain),
T24.3.2.1 anti-Thy 1, H129 anti-CD4, YTS169 anti-CD8, MI/70 anti-Mac
1, RB6–8C5 anti-Gr-1, and Ter119 antierythroid cell surface marker. These
antibodies were purified from hybridoma supernatant on protein G–Sepha-
rose columns (Amersham Biosciences) and conjugated to FITC, R-phyco-
erythrin (R-PE), cychrome 5 (Cy5), or biotin according to the manufac-
turer’s (Molecular Probes) instructions. Bound biotinylated antibodies were
revealed by R-PE–labeled streptavidin (Caltag). Stained cells were ana-
lyzed on a FACScan
® (Becton Dickinson), live and dead cells being dis-
criminated by staining with 2  g/ml propidium iodide (PI; Sigma-Aldrich)
and by their forward and side light scattering properties. Stable cell lines
were derived from fresh lymphomas by culturing in the high glucose ver-
sion of DME supplemented with 250  M asparagine, 50  M 2-mercapto-
ethanol, and 10% FCS. Genotyping of lymphomas and lymphoma cell
lines was performed by PCR as described in Mice section. Cell extracts
were Western blotted as described previously (Marsden et al., 2002) with
mAbs as follows: rat anti–Apaf-1 mAb 18H2 (Alexis Biochemicals), rat
anti–mouse caspase-2 mAb 10C6 (O’Reilly et al., 2002), rat anti–mouse
caspase-8 mAb 1G12, mouse anti–caspase-9 mAb (gift of Y. Lazebnik,
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), and mouse anti–
HSP-70 mAb (gift of R. Anderson, Peter MacCallum Cancer Centre, Mel-
bourne, Australia) or polyclonal rabbit anti–mouse caspase-1 antibody (gift
of P. Vandenabeele, Flanders Interuniversity Institute for Biotechnology,
Ghent, Belgium). HRP-conjugated goat anti–mouse Ig or goat anti–rat Ig
antibodies were used as secondary reagents, and bound antibodies were
revealed by ECL.
Stable lymphoma cell lines were sorted by flow cytometry using a modi-
fied FACSII
® or FACStar (Becton Dickinson). For cell death analysis, viable
cells (negative for PI) were cultured in DME at a concentration of 0.2–0.5  
10
6 cells/ml in 96-well flat bottom microtiter plates (Falcon). Cytotoxic stim-
uli used included the following: 10
 8–10
 6 M dexamethasone (Sigma-Aldrich),
0.01–1.0  g/ml etoposide (VP16; David Bull Laboratories), and  -radiation
(1–10 Gy from a 
60Co source). Cells were cultured for 24, 48, or 72 h, and
the fraction of viable cells was determined by staining with 2  g/ml PI and
FITC-coupled Annexin V followed by flow cytometric analysis.
Analysis of preneoplastic phenotype in reconstituted mice
Recipient mice showing no signs of lymphoma were killed and their or-
gans were harvested (cellularity refers to the total cell number in an organ).
Spleen cells (2   10
6) were injected intraperitoneally into nonirradiated
C57BL/6 mice to ensure no tumor development in the subsequent 3 mo.
pre–B cells (B220
 sIg
 ) and B cells (B220
 sIg
 ) were purified from the
bone marrow and lymph nodes, respectively, by immunofluorescent stain-
ing and sorting on a FACStar, DIVA (Becton Dickinson), or MoFlo (Dako-
Cytomation). Cells were cultured and viability determined over 6–72 h
as described in Lymphoma analysis. Donor-derived pro/pre–B cells
(c-kit
 B220
 CD19
 sIg
 Mac-1
 Gr-1
 Ter119
 Ly5.1
 ) were purified from
the bone marrow by immunofluorescent staining and FACS
® sorting (Cy5-
RA3-6B2, anti–CD45R-B220; Cy5-1D9, anti-CD19; biotin-ACK4, anti–
c-kit plus R-PE–streptavidin and FITC-labeled MI/70, anti–Mac-1; and
RB6-8C5, anti–Gr-1 and TER119) and cultured for 7–10 d on an ST-2
feeder cell layer in simple medium containing 100 U/ml IL-7. For induc-
tion of apoptosis, cells were exposed for 6 h to graded doses of etoposide
(VP16) or  -radiation (2.5 Gy) before plating at limiting dilution. B cell col-
onies consisting of at least 20 cells were scored blinded as to genotype us-
ing an inverted microscope at day 10, and the cloning frequency was de-
termined using limiting dilution analysis.
MEF culture and transformation
All MEFs (provided by T. Mak, University of Toronto, Toronto, Canada)
were maintained in full DME and were used between passage 2 and 3. For
long-term proliferation assays, 5,000 MEFs were resuspended in full DME
(normal glucose) supplemented with 100  g/ml hygromycin B plus 0.5  g/
ml puromycin and plated per 35-mm dish. Retroviral vectors were gener-
ated by transient cotransfection (calcium phosphate precipitation tech-
nique) of the respective vector plasmid and pCL-Eco (provided by I.M.
Verma, The Salk Institute, La Jolla, CA) in 293T cells. Virus-containing su-
pernatants were collected 48 and 72 h after transfection, cleared by filtra-
tion, and frozen until further use. Transductions were conducted in the
presence of 5  g/ml polybrene (Sigma-Aldrich). The vector plasmids
pBabePuro.H-ras (G12V), pLPC.E1A, pWZLH.E1A, pBabePuro.myc, and
pWZLH.myc were provided by S.W. Lowe and G. Hannon (Cold Spring
Harbor Laboratory). The vector plasmids pBabeHygro.H-ras and pBabe-
Puro.bcl-xL were generated by subcloning the respective cDNA into
pBabe. All inserts were verified by sequencing. The fraction of apoptotic
cells was determined by flow cytometry after staining with FITC-coupled
Annexin V (Calbiochem) and PI. Whole cell extracts were generated by re-
suspending cell pellets in lysis buffer (50 mM Hepes, 250 mM NaCl, 5 mM
EDTA, and 0.1% NP-40) on ice, followed by centrifugation. After transfer
onto nitrocellulose membranes (Amersham Biosciences), primary antibody
binding was detected by ECL (Pierce Chemical Co.). Primary antibodies
used were mouse anti-p53 (pAb 122, pAb 240; BD Biosciences), anti-E1A
(Oncogene Research Products), anti–H-ras (Oncogene Research Products),
anti-Myc (Santa Cruz Biotechnology, Inc.), and antiactin (clone C4; ICN).
Online supplemental material
Analysis of (Fig. S1 A) mice reconstituted with E -myc/Apaf-1
 / , E -myc/
Apaf-1
 / , E -myc/Apaf-1
 / , E -myc/E -bcl-2, or (Fig. S1 B) E -myc/cas-
pase-9
 / , E -myc/caspase-9
 / , E -myc/caspase-9
 / , or E -myc/E -bcl-2
stem cells counting all deaths (rather than only the deaths due to myc lym-
phoma; Fig. S3, A and B) demonstrates that loss of Apaf-1 or caspase-9
does not accelerate mortality caused by c-myc overexpression.
MEFs that are either wild type, p53
 / , bax
 /  (provided by S. Kors-
meyer, Dana Farber Laboratories, Boston, MA), or Apaf-1
 /  grew at simi-
lar rates in culture (Fig. S2 A). After infection with oncogene-containing
retroviruses, MEFs that were wild type, p53
 / , bax
 / , or Apaf-1
 /  all ex-
pressed similar levels of E1A plus mutant ras or myc plus mutant ras pro-
teins (Fig. S2 B).
Western blot analysis demonstrated that loss of Apaf-1 or caspase-9
does not cause a compensatory increase in expression or activation (after
 -radiation) of caspase-1, -2, -8, or -9 (in Apaf-1
 /  cells) in thymocytes.
Online supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200310041/DC1.
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